News & Publications

In an article published by VentureBeat, Partner Gary Schall lays out the critical post-financing actions that startups should take after closing their financing rounds.

The 2018 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest.

The 2018 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as provides a look at key issues to consider.

WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

The 2018 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.

Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, announced on June 19, 2018, the closing of a $55 million Series C financing.

On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing.

In the case of initial coin offerings (ICOs), the law is laid down by the US Securities and Exchange Commission. Over the past few months, this agency has been ramping up its warnings about ICOs that fail to comply with US securities laws. Read this article published by Bloomberg Law's Securities Regulation & Law Report, written by Jennifer Zepralka and Glenn Luinenburg.

Gary Schall, in this article published by The Recorder, shares six critical steps founders can take to forge a strong and open relationship with their new business partners.

An article by Joshua Fox, published by Law360, focusing on standardized term sheets and how they may inadvertently gloss over or neglect issues that can be critical to founders' long-term success.

An article by Daniel Zimmermann, published by Xconomy. The article discusses information that entrepreneurs should follow and what they can safely dismiss.

In 2017, we served as counsel in more than 250 venture financings raising over $4.5 billion, including some of the largest and most prominent deals of the year. Since 2007, we have handled more than 2,800 venture financings with total proceeds in excess of $35 billion.

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration. 

On February 28, 2018, Eko Devices, a leader in acoustic cardiac monitoring, announced that it closed $5 million in Series A funding to grow its commercial team and to expand clinical studies on the use of its platform for valvular heart disease screening and heart failure monitoring.

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing.